Genitope Reports Initial Results of MyVax Trial

Genitope Corporation announced that its pivotal Phase III clinical trial examining the use of MyVax personalized immunotherapy in previously untreated follicular B-cell non-Hodgkin’s lymphoma (fNHL) patients did not meet its primary endpoint.
Yahoo! Finance